1 Department of Otolaryngology-Head and Neck Surgery, University of Kansas School of Medicine, Kansas City, Kansas, USA.
2 Department of Anatomy and Cell Biology, University of Kansas School of Medicine, Kansas City, Kansas, USA.
Otolaryngol Head Neck Surg. 2018 Sep;159(3):572-575. doi: 10.1177/0194599818769879. Epub 2018 Apr 10.
Juvenile nasopharyngeal angiofibroma (JNA) is a highly vascularized and locally aggressive tumor that typically presents in adolescent males. The molecular biology of this tumor remains understudied. We sought to identify differentially expressed genes in the JNA transcriptome through messenger RNA sequencing of primary fibroblasts from 2 tumor explants and tonsil tissue from tumor-free subjects. In total, 1088 significant, differentially expressed genes were identified with 749 upregulated and 339 downregulated. Pathway analysis identified a number of activated signaling pathways, most notably, the vascular endothelial growth factor (VEGF) pathway (adjusted overlap P = .03). VEGF-A showed a 4.4-fold upregulation in JNA samples. In addition, the angiogenic receptor, fibroblast growth factor receptor 2 (FGFR2), was not present in tumor-free samples but increased in JNA. We validate these findings with immunohistochemistry, demonstrating upregulation of VEGF and FGFR2 in patient sections. Inhibition of the VEGF or FGFR signaling axes may have therapeutic potential in the treatment of JNA.
青少年鼻咽血管纤维瘤(JNA)是一种高度血管化和局部侵袭性肿瘤,通常发生在青少年男性中。该肿瘤的分子生物学仍研究不足。我们通过对 2 个肿瘤标本的原代成纤维细胞和无肿瘤扁桃体组织的信使 RNA 测序,试图在 JNA 转录组中识别差异表达的基因。总共鉴定出 1088 个显著差异表达的基因,其中 749 个上调,339 个下调。通路分析鉴定出许多激活的信号通路,最显著的是血管内皮生长因子(VEGF)通路(调整后的重叠 P =.03)。JNA 样本中 VEGF-A 的上调倍数为 4.4 倍。此外,无肿瘤样本中不存在血管生成受体成纤维细胞生长因子受体 2(FGFR2),但在 JNA 中增加。我们通过免疫组织化学验证了这些发现,表明患者切片中 VEGF 和 FGFR2 的上调。抑制 VEGF 或 FGFR 信号轴可能具有治疗 JNA 的潜在治疗作用。